Mydecine Innovations Group Inc. announced a positive meeting with the Food and Drug Administration regarding their Investigational New Drug and breakthrough therapy status applications. The Company reported a meeting with the FDA on February 28th to review their IND application to administer MYCO-001, in combination with therapy, to humans as part of smoking cessation treatment. Leading drug and substance abuse researcher, Dr. Matthew Johnson of Johns Hopkins University, will serve as the lead investigator for this multi-site study.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.01 USD | -18.26% |
|
0.00% | -32.89% |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-32.89% | 620K | |
+18.97% | 45.34B | |
+41.98% | 40.42B | |
-10.06% | 37.92B | |
+31.15% | 31.75B | |
-7.79% | 27.71B | |
+13.32% | 26.52B | |
+43.05% | 13.96B | |
+31.28% | 12.44B | |
-7.41% | 11.26B |
- Stock Market
- Equities
- MYCOF Stock
- News Mydecine Innovations Group Inc.
- Mydecine Innovations Group Inc. Reports Positive Pre-IND Meeting with FDA for MYCO-001 Smoking Cessation Study